Form 4: Actuate Therapeutics COO Andrew Mazar Acquires Stock Options
SEC Form 4 Filing
Andrew Paul Mazar, Chief Operating Officer of Actuate Therapeutics, acquired stock options on April 1, 2025, according to a Form 4 filing with the SEC.
Summary
- Andrew Paul Mazar, the Chief Operating Officer of Actuate Therapeutics, acquired employee stock options on April 1, 2025.
- He acquired 51,046 options with a strike price of $6.70, vesting 25% on April 1, 2026, and the remaining 75% in equal monthly installments over the following 36 months.
- Additionally, he acquired 110,346 options with a strike price of $6.70, vesting 25% on August 14, 2025, and the remaining 75% in equal monthly installments thereafter.
- The expiration date for both sets of options is March 31, 2035.
- Following these transactions, Mazar directly owns 51,046 and 110,346 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, suggesting confidence from the executive in the company's future.
Positives
- The acquisition of stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The vesting schedules described are typical, with a cliff vesting period followed by monthly installments.
- Comparable companies in the biotech sector, such as Amgen, Gilead Sciences, and Biogen, also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- The stock option grants could potentially incentivize the COO to improve company performance, benefiting shareholders.
- Employees may view the option grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of earliest transaction (grant date of stock options) |
| 04/01/2025 | Date of stock option acquisition |
| 08/14/2025 | First vesting date for 110,346 options |
| 04/01/2026 | First vesting date for 51,046 options |
| 03/31/2035 | Expiration date for all options |
| 04/02/2025 | Date of Form 4 filing |
Keywords
stock options, Form 4, Actuate Therapeutics, Andrew Paul Mazar, COO, insider trading, beneficial ownership, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.